Last reviewed · How we verify
ALGRX 4975
At a glance
| Generic name | ALGRX 4975 |
|---|---|
| Sponsor | AlgoRx Pharmaceuticals |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Sensory Function After Wound Instillation of Capsaicin
- Efficacy and Safety of ALGRX 4975 in Treatment of Postoperative Pain After Hernia Repair (PHASE2)
- ALGRX 4975 in the Treatment of Tennis Elbow (PHASE2)
- Efficacy and Safety of ALGRX 4975 in the Treatment of Postoperative Pain After Gall Bladder Removal (PHASE2)
- ALGRX 4975 After Total Knee Replacement (PHASE2)
- ALGRX 4975 in the Treatment of Patients With Morton's Neuroma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALGRX 4975 CI brief — competitive landscape report
- ALGRX 4975 updates RSS · CI watch RSS
- AlgoRx Pharmaceuticals portfolio CI